Signatera ASCO Presentations | Natera

Personalized tumor-informed test for actionable intelligence

Explore the three new studies recently presented at 2020 American Society of Clinical Oncology (ASCO) virtual conference and access additional content below. The oral presentation and 2 posters highlight the unique applications of Signatera to detect recurrence using circulating-tumor DNA (ctDNA).

On-Demand ASCO Presentations

ORAL PRESENTATION

Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy and to identify patients at high risk of recurrence in patients with stage I-III CRC

A study evaluating the validity of Signatera ctDNA assay to detect molecular residual disease (MRD) in CRC patients who are at high risk of recurrence, during and after adjuvant chemotherapy. Serial ctDNA analysis detected MRD up to 16.6 months before radiologic imaging.

ABSTRACT / POSTER: 4009 • 1

Noelia Tarazona, MD, PhD

Translational Researcher, INCLIVA Instituto de Investigación Sanitaria

Watch Presentation

POSTER PRESENTATION

Tumor informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced stage colorectal cancer (CRC MRD Consortia)

ABSTRACT / POSTER: 4108 • 100

Pashtoon Kasi, MD, MS

Assistant Professor, College of Medicine and Oncology, University of Iowa

Watch Presentation

Characterization of clonal hematopoiesis of indeterminate potential (CHIP) mutations from germline whole exome sequencing Data

ABSTRACT / POSTER: 1525 • 17

Hsin Ta Wu, PhD

Manager, Bioinformatics (Oncology & Algorithm Development), Natera

Watch Presentation

Dive Deeper

FOR PHYSICIANS

VIDEO

What are the Potential Clinical Applications of Signatera?

VIEW RESOURCE

ARTICLE

Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer

VIEW RESOURCE

WHITE PAPER

Seeing Beyond the Limit: Detect Residual Disease and Assess Treatment Response

VIEW RESOURCE

FOR CLINICAL RESEARCHERS

VIDEO

How can Signatera be Incorporated in Clinical Trials?

VIEW RESOURCE

ARTICLE

Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma

VIEW RESOURCE

WHITE PAPER

Detecting Molecular Residual Disease with Signatera

VIEW RESOURCE

View More Resources

Learn more

Presentations will be available for on-demand viewing and download.
Sign up here to receive access.